Overview

Update
Total Equity Funding
$149.33M in 3 Rounds from 12 Investors
Most Recent Funding
$79.14M Series C on April 26, 2015
Headquarters:
Utrecht
Description:
Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.
Founders:
Categories:
Therapeutics, Biotechnology, Medical
Website:
http://www.merus.nl

Company Details

Update

Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Funding Rounds (3) - $149.33M

Update
DateAmount / RoundValuationLead InvestorInvestors
Apr, 2015€72.8M / Series C10
Oct, 2013€31M / Series B5
Jan, 2010€21.7M / Series B4

Current Team (3)

Update

Board Members and Advisors (4)

Update

News (3)

Update
DateNews
Aug 26, 2015BioSpace - Merus Banks 72 8 Million Euro Series C
Oct 3, 2013FinSMEs - FinSMEs
Jan 31, 2010merus.nl - Merus raises 30306220 in venture round

Offices/Locations (1)

Update
  • Office

    Padualaan 8 (postvak 133)

    Utrecht, 3584 CH

    NLD

Past Team (1)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos